Effects of chemotherapy on quality of life and night-time sleep of colon cancer patients

Kozo Yoshikawa1), Jun Higashijima1), Hiroshi Okitsu2), Hidenori Miyake3), Toshiyuki Yagi4), Murato Miura5), Yoshiaki Bando6), Tsutomu Ando7), Masanori Hotchi8), Masashi Ishikawa9), Mitsutoshi Fukuyama10), Daisuke Wada11) and Mitsuo Shimada11)

1)Department of Surgery, Tokushima University, Tokushima, Japan, 2)Department of Surgery, Tokushima Red Cross Hospital, Tokushima, Japan, 3)Department of Surgery, Tokushima Municipal Hospital, Tokushima, Japan, 4)Department of Surgery, Tokushima Prefectural Central Hospital, Tokushima, Japan, 5)Department of Surgery, Yoshinogawa Medical center, Tokushima, Japan, 6)Department of Surgery, Tokushima Prefectural Naruto Hospital, Tokushima, Japan, 7)Department of Surgery, Tokushima Prefectural Miyoshi Hospital, Tokushima, Japan, 8)Department of Surgery, Ehime Prefectural Central Hospital, Ehime, Japan, 9)Department of Surgery, Shikoku Central Hospital, Ehime, Japan, 10)Department of Surgery, Kochi National Hospital, Kochi, Japan, 11)Department of Surgery, Takamatsu Municipal Hospital, Kagawa, Japan

Abstract: Background: The aim of this study was to investigate quality of life (QOL) and night-time sleep disturbances in colon cancer patients with middle risk chemotherapy for proper antiemetic therapy. Methods: The study enrolled 139 patients with colorectal cancer. All patients received oxaliplatin or irinotecan-based chemotherapy. Patients completed a questionnaire about chemotherapy-induced nausea and vomiting and sleep disturbances. Sleep disturbance was checked, and the relationship between sleep disturbance and nausea was analyzed. Results: The prevalence of nausea was 48.9% (68/139). The degree of nausea was slight/mild/moderate/severe in 51/48/24/6 patients, and 12 patients had vomiting. Appetite showed no change/slightly decreased/half/one-fourth/none in 51/34/33/6/7 patients. There were significant differences in the mental component summary (MCS) score and the role-social component score (RCS). (MCS: nausea(+) vs nausea(-) 46.4 ± 1.1 vs 54.1 ± 1.1 p < 0.01 RCS: nausea(+) vs nausea(-) 33.1 ± 2.1 vs 41.6 ± 2.1 p < 0.01). Using the MCS with a cut-off score of 50, patients were divided into two groups, and nausea was significantly correlated with a low MCS score. Furthermore, patients were divided into two groups using a Pittsburgh Sleep Quality Index cut-off score of 6, and sleep disturbance was correlated with old age and second-line chemotherapy. Conclusions: Nausea affects QOL and night-time sleep of colon cancer patients with middle risk chemotherapy. J. Med. Invest. 67:338-342, August, 2020

Keywords: Chemotherapy, QOL, Sleep disturbance

INTRODUCTION

Nausea and vomiting are frequent adverse events of cancer chemotherapy. Persistent nausea and vomiting are accompanied by decreased food and fluid intake, leading to dehydration, electrolyte abnormalities, weight loss, poor nutrition etc., which markedly decrease the patient's quality of life (QOL). Therefore, it is very important to control and minimize nausea and vomiting to enable continuation of cancer chemotherapy (1).

Despite the use of antiemetic prophylaxis, cancer patients experience significant chemotherapy-induced nausea and vomiting during 30% to 45% of cycles, which reduces their QOL. Among the risk factors for chemotherapy-induced nausea and vomiting (CINV), younger age, female sex, low alcohol consumption, and pregnancy-associated emesis or motion sickness are the commonly cited patient-related factors.

A few studies have suggested an association between sleep disturbance and CINV (2). The gastrointestinal system is closely linked with the central nervous system. A community study showed that overall gastrointestinal symptoms including nausea are related to sleep disturbances (3). Another study showed that nausea is associated with anxiety and depression. In the case of motion sickness, sleep deprivation can enhance susceptibility. Therefore, sleep and mood can be related to CINV. Moreover, since depression is prevalent in cancer patients, insomnia is three times more common than the 7.0% to 9.5% rate in the general population (4).

Whereas the development of antiemetic guidelines has helped to control the level of chemotherapy-induced vomiting (CIV), advances in the treatment of chemotherapy-induced nausea (CIN) are more limited. Moreover, CIN has a greater negative effect on patients' daily lives than CIV (3). In this regard, it would be helpful to assess the physiological and psychological factors associated with CIN and CIV in a relatively homogeneous study sample.

The aim of this study was to investigate QOL and night-time sleep of colon cancer patients with middle risk chemotherapy for proper antiemetic therapy.

PATIENTS & METHODS

Study Design and Setting

An open, multicenter, prospective, observational study was conducted in 11 general hospitals on Shikoku island in Japan. The protocol was approved by the clinical research ethics committees of all participating centers (TOCMS #1861). This study was conducted from April 2014 to March 2017. Clinical staff approached potentially eligible patients with colon cancer who visited individual departments. All participants provided written, informed consent.

Received for publication June 5, 2020; accepted July 27, 2020.
Address correspondence and reprint requests to Kozo Yoshikawa, MD, PhD, Department of Surgery, The University of Tokushima, 3-18-15 Kuramoto, Tokushima City, Tokushima, 770-8503, Japan and Fax: +81-88-631-9698.
**Patient Selection Criteria**

The study enrolled 139 patients aged 35 to 89 years old with colorectal cancer. All patients received oxaliplatin or irinotecan-based chemotherapy. There were no specific eligibility criteria.

**Patients’ characteristics**

The mean age of the patients was 64 (35-89) years, and there were 97 male and 42 female patients. Concerning the chemotherapy, 90 patients received first-line chemotherapy (oxaliplatin/irinotecan-based chemotherapy). There were no specific eligibility criteria.

Concerning the chemotherapy, 90 patients received first-line chemotherapy (oxaliplatin/irinotecan-based chemotherapy). There were no specific eligibility criteria. For antimetabolic prophylaxis, a 5-HT3, granisetron in 48 patients and palonosetron in 91 patients, was used. Aprepitant was used in 101 patients and not used in 38 patients. Stage was II/III/IV in 19/42/78 patients (Table 1).

**Table 1. Patient’s characteristics**

| Factor                        | n=139 |
|-------------------------------|-------|
| Age (M/F)                     | 64 (35-89) |
| Gender (M/F)                  | 97/42 |
| Line (first/beyond second)    | 90/49 |
| Regimen (Oxaliplatin/Irinotecan/Both) | 93/43/3 |
| 5-HT3 (Granisetron/Palonosetron) | 48/91 |
| Aprepitant (+/-)              | 101/38 |
| Stage (II/III/IV)             | 19/42/78 |

**Data Collection**

Patients who agreed to participate in the study completed a questionnaire about CINV and sleep disturbance and returned it at their next clinical visit. The questionnaires were sent to the University of Tokushima and analyzed. Clinical data (cancer stage and treatments received) were obtained from a review of medical records.

**Nausea, Vomiting, and Appetite loss**

Nausea and vomiting were evaluated using self-assessed questionnaires. Nausea was considered present if a symptom of nausea was present, and vomiting was considered present if there was vomiting over a period of 7 days. Appetite loss was considered present if there was “half of intake compared with ordinary oral intake”, “one-fourth compared with ordinary oral intake”, or “Hard to take water and meals”.

**QOL**

QOL was evaluated using the SF-36v2, and low QOL was defined as a total score lower than the national standard.

**SF-36v2**

The Optum SF-36v2 Health Survey asks 36 questions to measure functional health and well-being from the patient’s perspective. It is a practical, reliable, and valid measure of physical and mental health that can be completed in five to ten minutes. We refer to it as a generic health survey because it can be used across ages (18 and older), diseases, and treatment groups, as opposed to a disease-specific health survey, which focuses on a particular condition or disease. Meaningful to patients, clinicians, researchers, and administrators across the health care spectrum, the SF-36v2 has a variety of applications including: 1. measuring health improvement or decline; 2. predicting medical expenses; 3. assessing treatment effectiveness; and 4. comparing disease burden across populations.

The SF-36v2 provides scores for each of the eight health domains and psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores. Since the survey uses norm-based scoring, comparisons can be made with the other generic health surveys (SF-12v2 and SF-8). A preference-based utility index, called the SF-6D, is also available to help understand economic benefit. Multiple modes of administration are offered, including online, PDA, and more. The SF-36v2 is available in more than 170 translations for both standard four-week and acute one-week recall periods. This questionnaire consists of Physical functioning, Role physical, Bodily pain, General health, Vitality, Social functioning, Role emotional, and Mental health scores (5).

**Sleep-Related Factors**

Sleep quality and disturbance were assessed using the Pittsburgh Sleep Quality Index (PSQI), and a cut-off value of 6 was used to define significant poor sleep quality, which has been suggested for physically ill patients (6). The evaluation was done 7 days after the beginning of chemotherapy.

**Pittsburgh Sleep Quality Index (PSQI)**

The PSQI is a self-administered questionnaire to assess subjective sleep quality during the previous month. The self-rated items of the PSQI generate seven component scores (range of subscale scores, 0-3): sleep quality; sleep latency; sleep duration; habitual sleep efficiency; sleep disturbance; use of sleeping medication; and daytime dysfunction. The sum of these seven component scores yields one global score of subjective sleep quality (0-21), with higher scores representing poorer subjective sleep quality. The psychometric properties of the PSQI have been confirmed by previous studies (7).

**Data Analysis**

Bivariate correlations among nausea, vomiting, and sleep-related factors were evaluated. Univariable logistic regression analyses were conducted to examine variables associated with nausea and sleep disturbance. Statistical analyses were carried out using the JMP 10 statistical software package (SAS Institute Inc, Tokyo, Japan). Student’s t-test was used to compare continuous variables. A P-value of less than 0.05 was considered significant.

**RESULTS**

**Prevalence of nausea, vomiting, and appetite loss**

The prevalence of nausea was 48.9% (68/139). The degree of the nausea was slight/moderate/severe in 51/11/6 patients, and 12 patients reported vomiting. Appetite showed no change/slight decreased/half/one-fourth none in 51/34/33/6/7 patients.

**QOL**

The SF-36v2 consists of 8 parts, and the physical components consist of physical functioning, role physical, and bodily pain. The mental factor consists of role emotional and mental health. Both physical and mental factors consist of social functioning, general health perceptions, and vitality. For the physical component summary (PCS) score, mental component summary (MCS) score, and the role-social component score (RCS), there was a significant difference in the MCS and RCS scores (Figure 1) (MCS : nausea(+) vs nausea(-), 46.4 ± 1.1 vs 54.1 ± 1.1 p < 0.01 ; RCS : nausea(+) vs nausea(-), 33.1 ± 2.1 vs 41.6 ± 2.1 p < 0.01).
Sleep disturbance

Although there was no significant difference, there was a possible correlation between sleep disturbance and nausea (Figure 2).

Risk Factors for QOL and sleep disturbance

With an MCS cut-off score of 50, the patients were divided into two groups, and nausea was significantly correlated with a low MCS score (Table 2). Furthermore, patients were divided into two groups by a PSQI cut-off score of 6, and sleep disturbance was correlated with old age and second-line chemotherapy. Nausea was correlated with sleep disturbance, but it was not significant (Table 3).

Effect of antiemetic prophylaxis

There was no significant difference in the prevention of nausea and vomiting with and without aprepitant.

Table 2. Disturbance factor of MCS

| Factor               | MCS | p value |
|----------------------|-----|---------|
|                      | <50 (n=64) | >50 (n=75) |
| Age                  | 63.5 | 65.3 | n.s. |
| Gender               | M/F |        |       |
| Line                 | First/Second | 45/45 | 45/30 | n.s. |
| Nausea               | yes/no | 43/25 | 50/50 | <0.01 |
| Vomit                | yes/no | 9/44 | 3/57 | 0.06 |
| Apreptant            | yes/no | 44/20 | 57/18 | n.s. |

Table 3. Disturbance factor of night sleep

| Factor               | PSQI | p value |
|----------------------|------|---------|
|                      | <6 (n=69) | >6 (n=70) |
| Age                  | 62.4 | 66.5 | <0.05 |
| Gender               | M/F |        |       |
| Line                 | First/Second | 48/38 | 32/31 | <0.05 |
| Nausea               | yes/no | 29/39 | 40/31 | 0.1 |
| Vomit                | yes/no | 7/50 | 5/51 | n.s. |
| Apreptant            | yes/no | 49/50 | 52/18 | n.s. |

DISCUSSION

The present study showed that the incidence of nausea was 48.9%, but about 75% of it was low grade. Furthermore, the incidence of vomiting was about 10%. Despite the administration of optimal antiemetic prophylaxis, appetite loss (half or more) was observed in about 35% of patients. Nausea was found to be positively correlated with the MCS and RCS scores, and nausea had a negative effect on sleep. A low MCS score was significantly correlated with nausea. The factors associated with poor nighttime sleep were older age (>70 years old) and chemotherapy line (more than second-line).

The associations between the presence of nausea and MCS and RCS scores were remarkable, and the prevention of nausea is very important to maintain the QOL of patients on chemotherapy. Interestingly, the present study showed a strong negative impact on patients’ QOL with the presence of significant nausea or vomiting and their duration. In the present study, nausea had a higher impact on patients’ QOL than vomiting, and nausea had a negative effect not only on the MCS, but also on the RCS. This finding is crucial, because one of the goals of chemotherapy regimens is to maximize the doses, albeit with shorter duration regimens (8). Therefore, the duration of CINV should be taken into account when antiemetic prophylactic treatment is prescribed. As shown in the present study, the development of significant nausea has an important negative impact on patients’ QOL.

The present study examined the relationship between sleep and nausea in colorectal cancer patients. It was found that nausea was related to poor sleep quality, although not significantly, especially for elderly patients and patients with over second-line chemotherapy. Doctors who treat patients with chemotherapy take every effort to reduce the incidence of nausea. Prevention of nausea improves the quality of sleep and furthermore increases the QOL of patients on chemotherapy. As far as we are aware, few reports have examined sleep and nausea in colorectal cancer patients. In breast cancer patients, poor sleep quality was
associated with CINV after the first cycle of chemotherapy. Because an emesis response in the previous cycle is the strongest risk factor for CINV, clinicians should emphasize the management of poor sleep quality before a vicious cycle starts. The association between poor sleep quality and CINV may be alternatively explained by autonomic nervous system (ANS) dysfunction. Greater reactivity and arousal of the ANS have been reported in individuals with insomnia. Insomnia-related ANS arousals were demonstrated as decreased high-frequency power and increased low-frequency power in heart rate variability analyses. Similarly, chemotherapy-induced adverse effects including CINV and fatigue are reportedly related to increased activity and/or reactivity of the ANS. The present study showed that age and chemotherapy regimen line were predictors of sleep disturbance. In addition to the fact that sleep problems are more frequent in cancer patients, younger age and female sex are predisposing factors for insomnia. Thus, the risk factors are controversial. With respect to sleep disturbances, there are various aberrations that can occur in, for example, including total sleep time, sleep-onset latency, nocturnal awakenings, and wake time after sleep onset, as well as daytime napping with a circadian rhythm perceived sleep disturbance and use of sleep aids. The detailed reasons for a sleep disturbance should always be investigated.

Because newer agents such as aprepitant are not always effective at controlling CINV, olanzapine, a serotonin-dopamine receptor antagonist, has been suggested as a treatment for CINV. A recent study showed that olanzapine improved global health status, emotional functioning, and insomnia in cancer patients, in part by reducing the incidence of delayed CINV. The present study showed that poor sleep quality was significantly associated with CINV. Another psychiatric medication, mirtazapine, a noradrenergic and specific serotonin antidepressant, improves symptoms of nausea and insomnia in cancer patients. Sedative effects of olanzapine and mirtazapine might help the sleep problem to prevent CINV, in addition to stimulating appetite. These psychoactive drugs may act through receptors other than serotonin 5-HT3, such as histamine-1 or serotonin 5-HT2C. As there was a significant difference concerning chemotherapy line between PSQI score, the treatment with olanzapine and mirtazapine may be considered from the first line.

First, patients feel the nausea, the nausea affects sleep, and the disturbance of sleep affects the patient's mood. As a result, the incidence of nausea will increase. To break the vicious cycle, antiemetic prophylaxis is important. Aprepitant could be used as salvage antiemetic therapy in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Aprepitant did not contribute to decreasing the incidence of nausea and vomiting. In a previous study, aprepitant had a positive effect to prevent nausea. This was an observational study, it was not performed as a randomized, controlled study, the number in each group was different, and so on, resulting in no significant difference with aprepitant use.

The present study has several limitations. First, this study was performed with a single arm, and the number of patients enrolled was too small. Second, the period of the questionnaire was only 7 days and at only one point in time. Third, although the psychological condition affects this result, we didn't check the patient's psychological condition. Finally, this study was conducted in several institutions with different chemotherapy regimens, and chemotherapy regimens may have an effect.

CONCLUSION
Nausea affects the QOL and night-time sleep of colon cancer patients with middle risk chemotherapy, so that proper antiemetic therapy is needed.

CONFLICT OF INTEREST STATEMENT
Mitsuo Shimada received a research grant from Ono pharma, Chugai pharma and Taiho pharma. The other authors declare that they have no conflict of interest.

ACKNOWLEDGMENT
None.

COMPLIANCE WITH ETHICAL STANDARDS
This study was approved by The Ethics Committee of the Tokushima University Hospital, and patient information was obtained from their medical records [Approval number: 1861].

INFORMED CONSENT
Informed consent was obtained from all individual participants included in the study.

REFERENCES
1. Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, Fukuzaki T, Kudo T, Miyake Y, Yasui M, Morita S, Sakai D, Uemura M, Hata T, Takemasa I, Mizushima T, Ohno Y, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M, Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCGSO): Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51:1274-82, 2015
2. Molassiotis A, Aspro M, Dickato M, Gascon P, Novoa S, Isambert N, Burke T, Gu A, Roila F: Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47:839-848, 2014
3. Cremonini F, Camilleri M, Zinsmeister AR, Herrick LM, Beebe T, Talley NJ: Sleep disturbances are linked to both upper and lower gastrointestinal symptoms in the general population. Neurogastroenterol Motil 21:128-35, 2009
4. Irwin MR: Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes. Curr Psychiatry Rep 15:404, 2013
5. https://www.optum.com/solutions/life-sciences/answer-research/patient-insights/sf-health-surveys/sf-36v2-health-survey.html
6. Carpenter JS, Andrykowski MA: Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res 45:5-13, 1998
7. Doi Y, Minowa M, Uchiyama M, Okawa M, Kim K, Shibui K, Kamei Y: Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and
control subjects. Psychiatry Res 97: 165-72, 2000
8. Fernández-Ortega P, Caloto MT, Chirveches E, Marquilles R, San Francisco J, Quesada A, Suárez C, Zorrilla I, Gómez J, Zabaleta P, Nocea G, Llombart CA: Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life. Support Care Cancer 20: 3141-8, 2012
9. Jung D, Lee K, Kim WH, Lee JY, Kim TY, Im SA, Lee KH, Spiegel D, Hahn BJ: Longitudinal Association of Poor Sleep Quality With Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer. Psychosom Med 78: 959-965, 2016
10. Drake C, Richardson G, Roehrs T, Scofield H, Roth T: Vulnerability to stress-related sleep disturbance and hyperarousal. Sleep 15: 285-91, 2004
11. Bonnet MH, Arand DL: Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med 60: 610-5, 1998
12. Ataseven B, Frindte J, Harter P, Gebers G, Vogt C, Traut A, Breit E, Bluni V, Reinisch M, Heitz F, Kostara A, Kuenmel S, Prader S, Bommert M, Schneider S, Bois A: Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial. Support Care Cancer 11, 2019
13. Sekine I, Segawa Y, Kubota K, Saeki T: Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104: 711-7, 2013
14. Takemoto H, Nishimura J, Komori T, Kim HM, Ota H, Suzuki R, M I, Ikeda M, Yamamoto H, Satoh T, Hata T, Takemasa I, Mizushima T, Doki Y, Mori M, Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSCG): Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol 22: 88-95, 2017
15. Kotronoulas G, Wengström Y, Kearney N: A critical review of women’s sleep-wake patterns in the context of neo-adjuvant chemotherapy for early-stage breast cancer. Breast 21: 128-41, 2012
16. Kim SW, Shin IS, Kim JM, Kim YC, Kim KS, Kim KM, Yang SJ, Yoon JS: Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 62: 75-83, 2008
17. Joffe H, Massler A, Sharkey KM: Evaluation and management of sleep disturbance during the menopause transition. Semin Reprod Med 28: 404-21, 2010
18. Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, Duhmoush L, Penedo F, Lucci J, Thaker PH, Mendez L, Sood AK, Slavich GM, Lutgendorf SK: Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer 119: 3234-41, 2013